Treatment of Pediatric Hypertension With Altace Trial
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4
2002-07-01
Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of
hypertension since 1991. It has been shown to be effective in reducing both systolic and
diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used
to treat hypertension in children, however ramipril has not been extensively tested in
children, and information regarding the efficacy and safety would therefore be of benefit to
children. This study is designed to demonstrate the efficacy and safety of ramipril in the
treatment of hypertension in children ages 6 through 16 years.
Treatment of Pediatric Hypertension With Altace Trial
Completed
Pfizer
Phase 4
2002-07-01
Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of
hypertension since 1991. It has been shown to be effective in reducing both systolic and
diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used
to treat hypertension in children, however ramipril has not been extensively tested in
children, and information regarding the efficacy and safety would therefore be of benefit to
children. This study is designed to demonstrate the efficacy and safety of ramipril in the
treatment of hypertension in children ages 6 through 16 years.
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
Completed
Boehringer Ingelheim
Phase 4
2002-10-01
Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril
5mg & 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing
interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases.
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
Completed
Boehringer Ingelheim
Phase 3
2006-04-01
To identify dose combinations of telmisartan and ramipril that are more effective in reducing
diastolic blood pressure than each of the respective monotherapies in patients with Stage I
or II hypertension.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
